Categories: Market Research

Global Bioengineered Protein Drugs Market Size and Forecast 2024-2033|AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company

The Bioengineered Protein Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Bioengineered Protein Drugs Market:

https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report

According to The Business Research Company’s Bioengineered Protein Drugs Global Market Report 2024, The bioengineered protein drugs market size has grown strongly in recent years. It will grow from $379.36 billion in 2023 to $411.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased understanding of diseases, regulatory approvals, rising prevalence of chronic diseases, collaborations and partnership, market expansion

The bioengineered protein drugs market size is expected to see strong growth in the next few years. It will grow to $556.9 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to personalized medicine trends, expanding therapeutic applications, emerging markets, focus on rare diseases, healthcare infrastructure development. Major trends in the forecast period include advancements in protein engineering, increased focus on monoclonal antibodies, personalized medicine and targeted therapies, emergence of next-generation biologics, manufacturing process optimization

The increasing prevalence of chronic disease is expected to propel the growth of the bioengineered protein drug market going forward. Chronic diseases refer to those diseases from which people suffer for a year or longer, require continuous medical care, and restrict everyday physical activities. Bioengineered protein drugs are used for the treatment of chronic diseases with designer protein therapies for use in oncology and regenerative medicine using combinatorial and logical methodologies. For instance, in September 2022, according to the World Health Organization (WHO) 2022 Highlights, a Switzerland-based intergovernmental health organization, there were 41 million deaths, which is 74% of those caused by noncommunicable diseases (NCDs) or chronic diseases every year globally were 17.9 million deaths are from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths are from diabetes. Therefore, increasing chronic disease is driving the growth of bioengineered protein drugs.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp

The bioengineered protein drugs market covered in this report is segmented –

1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type

2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology

3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application

4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies

Product innovations are a key trend gaining popularity in the bioengineered protein drug market. Companies operating in the bioengineered protein drug market are adopting new technologies to sustain their position in the market. For instance, in July 2021, Janssen Pharmaceuticals, Inc., a Belgium-based pharmaceutical company, launched RYBREVANT, a Food and Drug Administration (FDA)-approved bioengineered protein drug. Rybrevant (amivantamab-vmjw) is a monoclonal antibody drug that is used to treat non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The technology used in the development of Rybrevant is a combination of molecular biology, cell culture, and protein engineering techniques. Rybrevant was developed using a phage display process, in which a library of antibodies is screened for those that bind specifically to the target protein.

The bioengineered protein drugs market report table of contents includes:

1. Executive Summary

2. Bioengineered Protein Drugs Market Characteristics

3. Bioengineered Protein Drugs Market Trends And Strategies

4. Bioengineered Protein Drugs Market – Macro Economic Scenario

5. Global Bioengineered Protein Drugs Market Size and Growth

26. South America Bioengineered Protein Drugs Market

27. Brazil Bioengineered Protein Drugs Market

28. Middle East Bioengineered Protein Drugs Market

29. Africa Bioengineered Protein Drugs Market

30. Bioengineered Protein Drugs Market Competitive Landscape And Company Profiles

Top Major Players: